Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tipranavir and Ritonavir in Healthy Volunteers
NCT02251132Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2000
- Primary completion
- Dec 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Trough plasma concentration at steady state up to 24 hours, Maximum plasma concentration at steady state up to 24 hours and 2 more. Started Oct 2000; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02251132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251132.